Prescriber Scope of Practice for ADHD in California

You’ve built your psychiatric practice around one core mission: getting patients the treatment they need. But when it comes to prescribing ADHD medications via telehealth, you’ve probably hit a wall of confusing, conflicting information about what’s actually legal.

Can you prescribe Adderall after a video consult? Do you need an in-person exam first? What about state rules—does Texas allow the same thing as California? And what happens when the DEA’s temporary COVID rules finally expire?

Here’s the reality: Yes, you can prescribe ADHD medications via telehealth in 2026—but the rules are temporary, state-specific, and about to change. If you’re a psychiatrist or PMHNP treating ADHD patients online (or considering it), you need to understand both the federal framework and your state’s specific requirements.

This guide breaks down exactly what’s legal right now, what’s changing, and how to stay compliant while building a sustainable telehealth ADHD practice.

The Federal Framework: Where We Stand in 2026

The Ryan Haight Act and COVID-Era Waivers

Under normal circumstances, federal law is clear: the Ryan Haight Act requires an in-person medical evaluation before prescribing any controlled substance, including ADHD medications like Adderall, Vyvanse, or Ritalin.

But we’re not operating under normal circumstances.

In March 2020, the DEA waived that in-person requirement during the COVID public health emergency. That waiver has been extended four times—most recently through December 31, 2026. Right now, you can legally prescribe Schedule II stimulants via telehealth without an initial in-person visit, as long as you:

• Conduct a proper evaluation via live audio-video (not just phone or questionnaire)
• Document a legitimate ADHD diagnosis following standard of care
• Use electronic prescribing for controlled substances
• Check your state’s Prescription Drug Monitoring Program (PDMP)
• Practice within your state licensure jurisdiction

This isn’t a permanent solution—it’s a bridge while the DEA finalizes new rules.

What’s Coming: The DEA’s Permanent Telemedicine Rules

In January 2025, the DEA announced three new telemedicine rules designed to make some flexibilities permanent while adding patient safeguards. Here’s what matters for ADHD prescribers:

Telemedicine Special Registration: The DEA is creating a pathway for providers to obtain special registration authorizing controlled substance prescribing without in-person exams. This will likely require:

• Mandatory nationwide PDMP checks (the DEA is building a national database hub)
• Strict patient identity verification during video consults
• Registration of telehealth platforms themselves (not just individual providers)

Established Patient Exception: If you’ve seen a patient in person at least once—even if it was by a colleague in your practice—you can continue prescribing via telehealth indefinitely without additional requirements.

Tiered Approach for New Patients: While final rule text hasn’t been published, the DEA is expected to allow initial stimulant prescriptions via telehealth with special registration, potentially with different rules for short-term versus ongoing treatment.

Bottom line: Plan to obtain the special registration when it becomes available (likely 2027) if you want to continue initiating ADHD treatment via telehealth for new patients.

The Economics No One Talks About

Let’s address the elephant in the room: patient acquisition cost.

If you tried to build your own ADHD telehealth practice from scratch, you’d face reality quickly. Acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ when you account for:

• SEO investment (6-12 months before meaningful results)
• Google Ads for mental health keywords ($15-40+ per click, with most clicks not converting)
• Directory listings that charge monthly fees AND put you in direct competition with hundreds of other providers
• Agency/consultant fees to actually execute the strategy
• Staff time to handle and qualify leads
• No-show rates from cold leads
• Failed campaigns and testing costs

Psychology Today? You’re on page 17 with 300 other providers in your city. Zocdoc? You’re paying $35-100+ per booking PLUS monthly subscription fees. Google Ads? You’re gambling $3,000-5,000/month with no guarantee of ROI.

DIY marketing can eventually work if you have deep pockets, marketing expertise, and patience. Most providers have none of those.

This is where a platform model makes economic sense. Instead of spending thousands upfront with uncertain results, you pay only when a pre-qualified patient books with you. No wasted ad spend. No monthly subscriptions bleeding you dry. No gambling on channels you don’t understand.

The trade-off is a per-appointment fee—but that’s guaranteed ROI versus playing roulette with your marketing budget.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Rules: The Details That Matter

Federal law sets the floor, but states can add restrictions. Here’s what you need to know in the six states with the highest demand for ADHD telehealth services.

California: Progressive and Permissive

The Good News: California explicitly allows telehealth exams to satisfy prescribing requirements—even asynchronous methods in some cases, though live video is best practice for ADHD. No state-imposed in-person exam requirement beyond federal law.

Licensure: You need a California medical license. CA isn’t part of the Interstate Medical Licensure Compact, so out-of-state physicians face a lengthy licensing process.

NP Scope: California is transitioning to Full Practice Authority for nurse practitioners. By 2026, experienced PMHNPs (3 years/4,600 hours under physician oversight) can prescribe ADHD medications independently. New grad NPs still need supervising physicians.

PDMP Requirements: You must check the CURES database before prescribing any Schedule II stimulant initially and every 4 months for ongoing therapy. This is mandatory and enforced.

Practical Reality: California’s provider shortage and tech-friendly regulations make it ideal for telehealth ADHD practice. Just ensure PDMP compliance and thorough documentation.

Texas: Physician-Only Stimulant Prescribing

The Restriction: Texas has one of the most limiting rules in the country—APRNs and PAs cannot prescribe Schedule II controlled substances in outpatient settings. Period.

The only exceptions are hospital inpatients (≥24 hours), hospice patients, or emergency orders in hospital ERs. Outpatient ADHD treatment doesn’t qualify.

What This Means: Only physicians (MD/DO) can prescribe Adderall, Vyvanse, or Ritalin to Texas patients. If you’re a PMHNP wanting to practice telehealth in Texas, you’ll need a collaborating psychiatrist to write the actual prescriptions.

For Psychiatrists: Texas allows full telehealth prescribing authority for mental health. Use the Interstate Medical Licensure Compact for faster licensing if you’re from another compact state.

PDMP: Texas requires checks for opioids, benzodiazepines, barbiturates, and carisoprodol—but not technically mandated for stimulants. Best practice is to check anyway.

Electronic Prescribing: Mandatory for all controlled substances in Texas (HB 2174). Ensure your EPCS system is set up before treating Texas patients.

Florida: The Psychiatric Disorder Exception

The Advantage: Florida law explicitly permits telehealth prescribing of Schedule II stimulants for ‘treatment of a psychiatric disorder’—which includes ADHD. This carve-out was intentional to ensure mental health access.

You cannot tele-prescribe Schedule II for other uses (pain management, weight loss), but ADHD treatment is explicitly allowed.

Out-of-State Registration: Florida offers a unique pathway—out-of-state providers can register to practice telehealth in Florida without obtaining a full Florida license. You must meet criteria (active unrestricted license elsewhere, clean disciplinary record for 5 years, malpractice insurance), but once registered you can treat Florida ADHD patients via telehealth and prescribe stimulants under the psychiatric exception.

NP Scope: Florida psychiatric nurse practitioners can prescribe stimulants without the 7-day limit that applies to other APRNs—but they must practice under a protocol agreement with a supervising psychiatrist. Florida hasn’t granted independence to psychiatric NPs (unlike primary care NPs).

PDMP: You must check Florida’s E-FORCSE database before prescribing controlled substances to patients 16 or older.

Bottom Line: Florida’s clear statutory framework actually makes compliance easier. Just document that you’re treating a psychiatric disorder and maintain PDMP checks.

New York: Recently Aligned with Federal Rules

May 2025 Update: New York updated its regulations to explicitly allow prescribing controlled substances via telehealth consistent with federal law. This removed state-level barriers that previously mirrored the Ryan Haight Act.

What’s Required:

• Check the I-STOP/PMP registry before prescribing any Schedule II, III, or IV controlled substance
• Use electronic prescribing (mandatory since 2016)
• Conduct evaluation via live two-way video

NP Scope: New York is favorable for psychiatric NPs. After 3,600 hours of practice, PMHNPs can practice independently without written collaborative agreements—including prescribing ADHD medications.

Unique Advantage: New York allows up to a 90-day supply of stimulants for ADHD if you indicate it’s for ADHD on the prescription (assign code ‘B’). This reduces refill frequency for stable patients—a real convenience in telehealth practice.

Licensure: New York isn’t part of the IMLC, so out-of-state psychiatrists need a full NY license. No shortcuts.

Pennsylvania: Collaborative Requirements for NPs

Telehealth Rules: Pennsylvania doesn’t prohibit telehealth prescribing of stimulants—the state defers to federal law and medical board guidelines emphasizing standard of care.

NP Limitations: CRNPs must have a collaborative agreement with a physician and are limited to 30-day supplies of Schedule II medications. Any continuation beyond 30 days requires the collaborating physician’s approval.

Practically, this means monthly physician oversight for ADHD patients being treated by NPs—either chart review or patient check-ins.

Psychiatrists: Full authority with no special state limitations. Pennsylvania is part of the IMLC for expedited licensing if you’re from another compact state.

PDMP: Required to check Pennsylvania’s PDMP before initial prescription of any controlled substance and periodically thereafter (mandatory for opioids/benzos each time; best practice for stimulants too).

Electronic Prescribing: Mandatory since 2019 (Act 96).

Illinois: Two-Tiered NP System

Telehealth Environment: Illinois is telehealth-friendly with insurance parity laws. No state-specific barriers to controlled substance prescribing via telemedicine beyond federal requirements.

NP Scope – Two Pathways:

Full Practice Authority: APRNs who complete 4,000 hours under physician collaboration plus 250 hours of continuing education can apply for FPA status. These providers can prescribe ADHD medications independently—no physician consultation required for stimulants (the consultation requirement only applies to Schedule II narcotics and benzodiazepines, not amphetamines).

Under Collaboration: Non-FPA NPs are limited to 30-day supplies of Schedule II substances with physician approval required for continuation. The collaborating physician must also conduct monthly reviews of the NP’s Schedule II prescribing.

Licensure: Illinois requires a state controlled substance license in addition to DEA registration. Out-of-state physicians can use IMLC for faster licensing.

PDMP: Not explicitly mandated for stimulants but required for opioids and first-time benzodiazepines. Best practice is to check before prescribing ADHD medications.

State Rules Comparison Table

What You Must Do to Stay Compliant

Regardless of your state, here’s your compliance checklist:

Before Prescribing:

1. Verify state licensure for patient’s location
2. Obtain DEA registration covering that state
3. Set up electronic prescribing system (EPCS-certified)
4. Register with state PDMP and learn how to check it
5. Understand your state’s specific NP scope requirements

For Each ADHD Patient:

1. Conduct live audio-video evaluation (not just phone)
2. Document thorough ADHD assessment following DSM-5 criteria
3. Check state PDMP for controlled substance history
4. Verify patient identity and location
5. Issue e-prescription only (paper prescriptions for Schedule II are largely banned)
6. Document evaluation and prescribing rationale clearly

Ongoing:

1. Check PDMP at required intervals (state-specific: every time in NY, every 4 months in CA, etc.)
2. Monitor DEA rule updates for special registration requirements
3. Keep CE current on controlled substance prescribing and telehealth standards
4. Maintain documentation that would satisfy standard of care review

The Coming Changes: What to Prepare For

The DEA’s permanent rules will likely take effect in 2027. Start preparing now:

Get Ready for Special Registration: Budget time and fees to obtain telemedicine special registration when available. This will likely become mandatory for prescribing to new patients you’ve never seen in person.

Implement Enhanced Identity Verification: The DEA will require stricter patient identification. Ensure your telehealth platform has robust identity verification tools.

Automate PDMP Checks: If the DEA creates a national PDMP hub, integration will be critical. Choose platforms and EHR systems that can automate checks.

Document, Document, Document: When regulations tighten, thorough documentation of your evaluation process and clinical decision-making becomes your liability shield.

Why Platform Models Make Sense for ADHD Telehealth

Building your own ADHD telehealth practice means:

• 6-12 months of SEO work before meaningful traffic
• $3,000-5,000/month in marketing spend with uncertain ROI
• Competing with hundreds of providers on directories
• Managing your own telehealth technology stack
• Handling your own credentialing and licensing
• Absorbing the cost of no-shows and unqualified leads

Or you could join a platform that:

• Delivers pre-qualified, matched patients to your schedule
• Handles all marketing and patient acquisition
• Provides built-in HIPAA-compliant telehealth infrastructure
• Manages credentialing and insurance contracting
• Charges only when you see patients (true pay-per-appointment model)

You pay a standard fee per new patient, but you avoid the risk entirely. No upfront spend. No wasted ad budget. No gambling on channels you don’t understand.

For psychiatrists and PMHNPs treating ADHD, especially those starting out or expanding to new states, platforms remove the biggest barrier: patient acquisition cost and risk.

The Bottom Line for ADHD Prescribers

Right now (through December 2026): You can prescribe ADHD medications via telehealth without in-person exams in all states that license you, following federal temporary rules.

Soon (2027 and beyond): You’ll need DEA special registration and must comply with enhanced safeguards, but telehealth ADHD prescribing will remain viable.

State variations matter: Texas restricts NPs entirely. Florida and California offer clear pathways. New York and Illinois have favorable NP independence laws. Pennsylvania requires closer physician collaboration.

Economics matter more: Don’t gamble thousands on marketing channels you don’t understand. Platform models remove acquisition risk and let you focus on what you do best—treating patients.

The telehealth ADHD treatment landscape is complex, but it’s not impenetrable. The providers who succeed are those who understand the regulations, stay ahead of changes, and choose practice models that eliminate patient acquisition risk.

If you’re a psychiatrist or PMHNP ready to expand your ADHD practice via telehealth without the marketing gamble, now is the time to position yourself before the DEA’s permanent rules take effect.

Frequently Asked Questions

Can I prescribe Adderall via telehealth in 2026?
Yes, through December 31, 2026, federal law allows prescribing Schedule II stimulants like Adderall via telehealth without an in-person exam, as long as you conduct a proper live video evaluation. After 2026, you’ll likely need DEA special registration for new patients you haven’t seen in person.

Do PMHNPs have the same prescribing authority as psychiatrists for ADHD medications?
It depends on your state. PMHNPs can prescribe ADHD medications in all 50 states, but scope varies. States like California, New York, and Illinois (with FPA) allow independent prescribing. Texas prohibits NPs from prescribing Schedule II stimulants in outpatient settings entirely. Pennsylvania and Florida require physician collaboration with specific limitations.

What happens if I don’t check the state PDMP before prescribing?
Most states mandate PDMP checks for controlled substances—failure to check can result in medical board disciplinary action, DEA scrutiny, or even loss of prescribing privileges. California requires checks every 4 months for Schedule II. New York requires checks every time. Even where not explicitly mandated, PDMP checks are standard of care.

Can I use audio-only telehealth to prescribe ADHD medications?
No. Federal DEA guidance requires live two-way interactive audio-video communication for prescribing controlled substances via telehealth. Phone calls don’t meet this standard. You need video.

What’s the best state for telehealth ADHD practice?
California, Florida, and New York offer the most favorable regulatory environments with clear telehealth rules and (for CA and NY) advancing NP independence. Florida’s out-of-state registration option is unique. Texas is most restrictive for NPs. All states require proper licensure.

How much does it really cost to acquire ADHD patients through marketing?
Realistically, $200-500+ per booked patient when accounting for all costs—ad spend, agency fees, staff time, no-shows, testing, and the 6-12 months of SEO investment before results. DIY marketing works if you have budget and expertise, but platforms that charge per appointment eliminate the upfront risk entirely.

Will the DEA make telehealth ADHD prescribing illegal after 2026?
No. The DEA is creating permanent rules to allow telehealth prescribing with safeguards (special registration, PDMP checks, identity verification). The goal is to maintain access while preventing abuse. Expect some new requirements but not a return to mandatory in-person exams for all cases.

References and Citations

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026, U.S. Department of Health and Human Services, January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. Olsen, E., ‘DEA, HHS extend telehealth controlled substance prescribing flexibilities for fourth time,’ Healthcare Dive, January 5, 2026. https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/

3. DEA Press Release – DEA Announces Three New Telemedicine Rules to Continue Open Access, U.S. Drug Enforcement Administration, January 16, 2025. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

4. Nurse Practitioner Prescriptive Authority by State: 2026 Complete Guide, RxAgent, December 28, 2025. https://rxagent.co/blog/np-prescribing-authority

5. New York State Department of Health, Bureau of Narcotic Enforcement, ‘Guidance on Prescribing Controlled Substances via Telehealth,’ effective May 21, 2025. https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care